Acorda Therapeutics (ACOR) Reports Q3 EPS of 28c

Acorda Therapeutics (NASDAQ: ACOR) reported Q3 EPS of $0.28, may not compare to the analyst estimate of $0.05. Revenue for the quarter came in at $106 million versus the consensus estimate of $94.7 million.

It raised full year 2014 guidance for AMPYRA net revenue from $328-$335 million to $345-$350 million

For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• UBS says bull market has further to run
• Deere & Co. (DE) Tops Q3 EPS by 41c, raises guidance